You are about to access information on our medicines and medical devices aimed exclusively at healthcare professionals.

By virtue of Spanish Royal Decree 1416/1994 of 25 June regulating the advertising of medicinal products for human use, Spanish Royal Decree 1591/2009 of 16 October regulating medical devices and Law 29/2006 of 26 July on the guarantees and rational use of medicines and health products, in this section Bioibérica can only offer advertising content of prescription medicines to health personnel authorised to prescribe or dispense them.

I am a health professional authorised to prescribe or dispense, or a pharma company professional.

You are here

Bioiberica to explore new partnerships for future health solutions at CPhI 2019

25 Oct 2019
  • Bioiberica will highlight how can support pharmaceutical manufacturers to develop future health solutions
  • The Bioiberica team will be at stand 61D51 to explore new partnerships

Bioiberica, a global life science company committed to the health and wellbeing of people worldwide, will highlight how its world-leading expertise in animal-derived APIs, vertically integrated supply chain and commitment to industrial excellence, can support pharmaceutical manufacturers to develop future health solutions at CPhI 2019. The Bioiberica team will be at stand 61D51 to explore new partnerships with drug manufacturers and enable the development of the health solutions of tomorrow.

Supporting business development

To assist drug manufacturers in meeting the world’s evolving healthcare needs, Bioiberica is actively looking for strategic industry partnerships, so that together, we can jointly explore the growing business opportunities the pharmaceutical market has to offer. We aim to do this by; creating tailor-made products, delivering pilot manufacturing and scale-up services, developing analytical methods that characterize highly complex molecules and providing regulatory support – all to help successfully bring products to market,” comments Javier Velasco, R&D Director, Bioiberica S.A.U.

He continues: “A hotbed of pharmaceutical innovation, CPhI presents the ideal opportunity to explore these partnerships, as well as identify opportunities in specific areas, such as glycosaminoglycans, complex lipids, proteins and bioactive peptides of non-recombinant origin.”

Putting the spotlight on its newly developed API – thyroid – for the treatment of hypothyroidism, visitors to the Bioiberica stand will discover how it can aid the development of novel pharma solutions for improved patient outcomes. An example of how the company drives innovations through collaborative partnerships, thyroid provides a natural choice for hypothyroidism and its associated symptoms.

Animal-derived API experts

With more than 40 years’ experience in the identification, extraction and production of animal-derived APIs, Bioiberica experts will be available during the show to highlight how the company’s unique extraction technology can help drug manufacturers activate and accelerate successful pharmaceutical solutions. As well as thyroid, Bioiberica will present additional APIs and science-backed ingredients from its comprehensive portfolio, including chondroitin sulphate, glucosamine and native type II collagen for joint health and mobility.

From our roots in heparin API manufacturing – the most used anti-coagulant drug across the globe – to our expertise in the identification and extraction of other animal-derived APIs, we are committed to empowering our customers with the scientific, regulatory, industrial and market knowledge they need to take healthcare further”, says Jaume Reguant, Healthcare Director, Bioiberica S.A.U. “Our production capacity and vertically-integrated supply chain guarantees full traceability, security and sustainability, as well as API quality, safety and regulatory compliance. Bioiberica is the active ingredient for innovation and we’re looking forward to exploring new partnerships with manufacturers at CPhI to inspire the next breakthrough product on the market.”

About Bioiberica:

Bioiberica is a global Life Science company committed to improving people, animal, and plant health and well-being. Our core business is the identification, extraction and development of animal-derived biomolecules, which are transformed into high quality products for the pharmaceutical, nutraceutical, veterinary, feed and agricultural industries. This specialisation has positioned us as the leading Heparin API manufacturer and a world reference in the research, production and sale of other animal-derived APIs, ingredients and compounds, such us chondroitin sulfate, glucosamine, hyaluronic acid, native type II collagen or thyroid.

Related News

23 Jan 2024

On a planet where natural resources are limited and there is increasing concern for the environment, the circular economy has emerged as an innovative and sustainable solution.

16 Oct 2023

We participated in CPHI 2023 in Barcelona, ​​where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.

4 May 2023

They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs